Contact
Score Calculators

News & Events

EventsMedia coverage
  • Articles

First face-to-face meeting of the Inspiring & Writing Group

After the establishment of the Inspiring and Writing Group early in 2022, members of this working group met for the first time in person at the EF CLIF Headquarters in Barcelona, Spain, to present ancillary studies from CANONIC, PREDICT, and ACLARA.
BARCELONA—The Inspiring and Writing Group works across disciplines and brings together expertise in end-stage liver disease, liver transplantation, critical care, gut microbiome, hepatic vascular disorders, hepatic encephalopathy, acute kidney injury, and liver regeneration. On the first face-to-face meeting of the Inspiring and Writing Group, members which project proposal was successful in an internal call, presented the rationale behind their project and expected outcomes.

Paolo Angeli, Chair of the EASL-CLIF Consortium Steering Committee, encouraged the audience to share knowledge for the advancement of chronic liver disease research with great enthusiasm during the opening session.

Our Scientific Director, Rajiv Jalan, presented the future scientific directions of the EF CLIF highlighting the importance of cross-sector collaboration. Jalan called members of the Inspiring and Writing Group to contribute to help us bridge the gaps in the existing literature to provide the basis for new therapeutic solutions for patients with chronic liver failure.

Cristina Sánchez-Garrido, Head of the Data Management Center, provided a detailed description of study designs and case report forms for the studies CANONIC, PREDICT and ACLARA.

Our General Manager, Anna Bosch, presented the process for project proposal submission and evaluation by the Sample and Data Usage Committee.

Next, Thierry Gustot, Principal Investigator of CHANCE who serves as the Vice-Chair of the EASL-CLIF Consortium and Chair of the Inspiring and Writing Group, presented and overview and preliminary results of the CHANCE study – Liver transplantation in patients with cirrhosis and severe acute-on-chronic liver failure: Indications and outcomes.

Jonel Trebicka, Principal Investigator of PREDICT and Coordinator of the EU-funded project MICROB-PREDICT – Microbiome-based biomarkers to predict decompensation of liver cirrhosis and treatment response, presented the current status of this project and provided a comprehensive review of many other ancillaries of the PREDICT study.

Pierre-Emmanuel Rautou, Coordinator of the EU-funded project DECISION – Decompensated cirrhosis: Identification of new combinatorial therapies based on systems approaches, presented an overview of the project and shared some preliminary results based on data from former studies CANONIC, PREDICT and ACLARA.

After the presentations of recently approved projects, Gustot thanked members of the Inspiring and Writing Group for the collaborative effort and continued support during the closing session.